LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 12 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 2. - Dataset (ID:20249)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MCF7 | Barasertib | 10 | uM | LJP5 | 72 | hr | 1389 | 1663 | 5905 | 0.2820 | 0.0904 |
| MCF7 | Vemurafenib | 0.04 | uM | LJP5 | 72 | hr | 1389 | 5823 | 5905 | 0.9859 | 0.9864 |
| MCF7 | Vemurafenib | 0.12 | uM | LJP5 | 72 | hr | 1389 | 5909 | 5905 | 1.0012 | 1.0013 |
| MCF7 | Vemurafenib | 0.37 | uM | LJP5 | 72 | hr | 1389 | 6152 | 5905 | 1.0425 | 1.0406 |
| MCF7 | Vemurafenib | 1.11 | uM | LJP5 | 72 | hr | 1389 | 6263 | 5905 | 1.0611 | 1.0579 |
| MCF7 | Vemurafenib | 3.33 | uM | LJP5 | 72 | hr | 1389 | 5927 | 5905 | 1.0052 | 1.0049 |
| MCF7 | Vemurafenib | 10 | uM | LJP5 | 72 | hr | 1389 | 5618 | 5905 | 0.9517 | 0.9533 |
| MCF7 | Enzastaurin | 0.04 | uM | LJP5 | 72 | hr | 1389 | 6139 | 5905 | 1.0394 | 1.0373 |
| MCF7 | Enzastaurin | 0.12 | uM | LJP5 | 72 | hr | 1389 | 5864 | 5905 | 0.9938 | 0.9942 |
| MCF7 | Enzastaurin | 0.37 | uM | LJP5 | 72 | hr | 1389 | 6125 | 5905 | 1.0364 | 1.0338 |
| MCF7 | Enzastaurin | 1.11 | uM | LJP5 | 72 | hr | 1389 | 5842 | 5905 | 0.9887 | 0.9886 |
| MCF7 | Enzastaurin | 3.33 | uM | LJP5 | 72 | hr | 1389 | 6070 | 5905 | 1.0269 | 1.0244 |
| MCF7 | Enzastaurin | 10 | uM | LJP5 | 72 | hr | 1389 | 6072 | 5905 | 1.0283 | 1.0270 |
| MCF7 | Palbociclib | 0.04 | uM | LJP6 | 72 | hr | 1389 | 4400 | 5445 | 0.8075 | 0.7926 |
| MCF7 | Palbociclib | 0.12 | uM | LJP6 | 72 | hr | 1389 | 3951 | 5445 | 0.7250 | 0.6976 |
| MCF7 | Palbociclib | 0.37 | uM | LJP6 | 72 | hr | 1389 | 3632 | 5445 | 0.6662 | 0.6259 |
| MCF7 | Palbociclib | 1.11 | uM | LJP6 | 72 | hr | 1389 | 3058 | 5445 | 0.5622 | 0.4926 |
| MCF7 | Palbociclib | 3.33 | uM | LJP6 | 72 | hr | 1389 | 2633 | 5445 | 0.4835 | 0.3822 |
| MCF7 | Palbociclib | 10 | uM | LJP6 | 72 | hr | 1389 | 2357 | 5445 | 0.4325 | 0.3057 |
| MCF7 | PF562271 | 0.04 | uM | LJP6 | 72 | hr | 1389 | 4722 | 5445 | 0.8668 | 0.8594 |
| MCF7 | PF562271 | 0.12 | uM | LJP6 | 72 | hr | 1389 | 4397 | 5445 | 0.8077 | 0.7942 |
| MCF7 | PF562271 | 0.37 | uM | LJP6 | 72 | hr | 1389 | 3527 | 5445 | 0.6477 | 0.6036 |
| MCF7 | PF562271 | 1.11 | uM | LJP6 | 72 | hr | 1389 | 2503 | 5445 | 0.4590 | 0.3457 |
| MCF7 | PF562271 | 3.33 | uM | LJP6 | 72 | hr | 1389 | 1233 | 5445 | 0.2267 | -0.0590 |
| MCF7 | PF562271 | 10 | uM | LJP6 | 72 | hr | 1389 | 532 | 5445 | 0.0972 | -0.3885 |